Sections

Home
News
Analysis
Pharma
Themes
Insights
Companies
Webinar & Events
Buy Reports
Excellence Awards
Innovation Rankings
Magazine
Newsletters

GlobalData

About us
Advertise With Us
Contact Us
Our Marketing Solutions
GlobalData Reports
Visit GlobalData

From Our Partners

Biopharma Playbooks: Solutions at the Speed of Science
Simplifying clinical data processes
Control and confidence in clinical data management
Accelerating Biopharmaceutical Innovation
Precision medicine and digital health innovation for disease diagnosis, care and treatment
The next chapter of clinical trial services
Putting quality first in the pharma supply chain
Maximising molecule potential

News
Analysis
Sections
Latest
Pharma
Sections
Latest
Themes
Sections
Latest
Insights
Sections
Latest
Companies
Sections
Latest
Webinar & Events
Sections
Latest
Buy Reports
Newsletters

PT

Analysis

Left

Right

Features
Comment & Opinion
Projects
Data Insights

Data Insights

Filter search results

By Company Name

No Filter Selected

By Disease Name

No Filter Selected

By Drug Name

No Filter Selected

By Themes

No Filter Selected

Showing 3 results out of 3

Industry Themes and Signals

Decode the future of Pharmaceuticals. Access unrivalled intelligence on new technologies, macroeconomic shifts and social trends.

Get the insights you need to stay one step ahead - from smart cities to artificial intelligence, from nanomedicine to de-globalization.
Or go granular and access the latest signals on deals, filings, patents, hiring activities and more!

Data Insights

Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Arlocabtagene autoleucel?

Arlocabtagene autoleucel is a gene-modified cell therapy commercialized by Bristol-Myers Squibb, with a leading Phase II program in Relapsed Multiple...

Net Present Value Model: Bristol-Myers Squibb Co's arlocabtagene autoleucel

Data Insights

Arlocabtagene autoleucel by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval

Arlocabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Arlocabtagene Autoleucel in Relapsed Multiple Myeloma

Data Insights

Arlocabtagene autoleucel by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval

Arlocabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Refractory Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Arlocabtagene Autoleucel in Refractory Multiple Myeloma

The leading site for news and procurement in the pharmaceutical industry

About us
Advertise with us
License our content
Contact us
Editorial approach
Newsletters
Our marketing solutions

Privacy policy
Terms and conditions
Sitemap

Powered by

Lost Password Back ⟶
Login
Register

Lost Password?

Registration is disabled.